Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Capital Leases (2016 - 2018)

Kiora Pharmaceuticals (KPRX) has disclosed Capital Leases for 3 consecutive years, with $140.0 as the latest value for Q3 2018.

  • For the quarter ending Q3 2018, Capital Leases fell 97.87% year-over-year to $140.0, compared with a TTM value of $140.0 through Sep 2018, down 97.87%, and an annual FY2017 reading of $4855.0, down 69.79% over the prior year.
  • Capital Leases was $140.0 for Q3 2018 at Kiora Pharmaceuticals, down from $1712.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $16069.0 in Q4 2016 and bottomed at $140.0 in Q3 2018.
  • Average Capital Leases over 3 years is $6912.1, with a median of $5720.0 recorded in 2017.
  • The sharpest move saw Capital Leases crashed 69.79% in 2017, then tumbled 97.87% in 2018.
  • Year by year, Capital Leases stood at $16069.0 in 2016, then plummeted by 69.79% to $4855.0 in 2017, then plummeted by 97.12% to $140.0 in 2018.
  • Business Quant data shows Capital Leases for KPRX at $140.0 in Q3 2018, $1712.0 in Q2 2018, and $3283.0 in Q1 2018.